MYGN analyst estimates
Myriad Genetics (MYGN) analyst ratings, the average price target and its range, and every firm's latest call.
MYGN analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 20, 2026 | Piper Sandler | Myriad Genetics upgraded to Neutral from Underweight at Piper Sandler | $5.00 |
| Oct 20, 2026 | Wells Fargo | TD Cowen Reiterates Hold Rating on Myriad Genetics (MYGN) | $4.50 |
| Oct 2, 2026 | Craig-Hallum | Myriad Genetics price target raised to $8 from $4 at Craig-Hallum | $8.00 |
| Sep 9, 2026 | UBS | Myriad Genetics assumed with a Neutral at UBS | $3.60 |
| Sep 1, 2026 | Piper Sandler | Myriad Genetics downgraded to Underweight from Overweight at Piper Sandler | $2.00 |
| Aug 18, 2026 | Stephens | Myriad Genetics price target lowered to $3 from $5 at Stephens | $3.00 |
| Aug 3, 2026 | Wells Fargo | Myriad Genetics price target lowered to $3 from $5.50 at Wells Fargo | $3.00 |
| Feb 24, 2026 | UBS | Myriad Genetics price target lowered to $6 from $8 at UBS | $6.00 |
| Nov 4, 2025 | UBS | Myriad Genetics price target raised to $8 from $6 at UBS | $8.00 |
| May 7, 2025 | Wells Fargo | Myriad Genetics downgraded to Equal Weight from Overweight at Wells Fargo | $6.00 |
| May 7, 2025 | UBS | Myriad Genetics price target lowered to $7 from $16 at UBS | $7.00 |
| May 7, 2025 | Craig-Hallum | Myriad Genetics price target lowered to $18 from $29 at Craig-Hallum | $18.00 |
| Mar 12, 2025 | Piper Sandler | Myriad Genetics upgraded to Overweight from Neutral at Piper Sandler | $12.50 |
| Mar 4, 2025 | Piper Sandler | Myriad Genetics price target lowered to $11.50 from $14 at Piper Sandler | $11.50 |
| Dec 9, 2024 | Leerink Partners | Leerink Partners Downgrades Myriad Genetics (MYGN) to Market Perform | $21.00 |
- 6 firms rate MYGN: 1 buy, 4 hold, 1 sell.
- The average price target is $4.82 from 5 analysts, from $3.00 to $8.00.
Updated 2026-11-05 12:48 UTC